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1INTEREST OF AMICI CURIAE1
Amicus curiae James D. Watson, Ph.D., is the co-
discoverer of the double helix structure of deoxyribonucleic 
acid (“DNA”). For this discovery, he and his colleague, the 
late Francis Crick (along with the late Maurice Wilkins for 
related work), were awarded the Nobel Prize in Physiology 
or Medicine in 1962. See James D. Watson, The Double 
Helix (1968).
Throughout his career, Dr. Watson has been at the 
forefront of recombinant DNA research and advances in 
genetic engineering. From 1956 until 1976, Dr. Watson was 
on the faculty of Harvard University, leading the effort to 
focus the biology department on the then-emerging  eld 
of molecular biology. Starting in 1968, Dr. Watson was the 
director of Cold Spring Harbor Laboratory (“CSHL”). 
From 1994 to 2004, he served as the president of CSHL, 
and from 2004 until 2007, he was CSHL’s Chancellor. Dr. 
Watson is now Chancellor Emeritus of CSHL.
Dr. Watson’s current research relates to the causes 
and potential cures of cancers. His interest in cancer  rst 
publicly expressed itself through his teaching on tumor 
viruses after he joined the Harvard University Biology 
Department in the fall of 1956. At that early stage, his 
1. The petitioners have  led a letter of blanket consent to 
amici on January 2, 2013. Respondents granted consent to amicus 
on January 9, 2013, via electronic mail, a copy of which is being 
submitted herewith. Amicus and his counsel represent that no 
party to this case nor their counsel authored this brief in whole 
or in part, and that no person other than amicus paid for or made 
a monetary contribution toward the preparation and submission 
of this brief.
2lectures explored how cancer might be induced by DNA 
tumor viruses, the smallest of which probably had DNA 
suf cient to code for only 3–5 proteins. His expertise 
with recombinant DNA and cancer research lends 
particular insight into the case at hand, which concerns 
the patentability of human genes relating to breast cancer.
The author of numerous books and research articles, 
Dr. Watson has received several honors for his scienti c 
research, including the Albert Lasker Prize (1960), the 
Nobel Prize in Physiology or Medicine (1962), the John J. 
Carty Gold Medal of the National Academy of Sciences 
(1971), the Presidential Medal of Freedom (1977), the 
Copley Medal of the British Royal Society (1993), the 
Lomonosov Medal, Russian Academy of Sciences (1995), 
the National Medal of Science awarded by the National 
Science Foundation (1997), the University of Chicago 
Medal (1998), the New York Academy of Medicine Award 
(1999), the University College London Prize (2000), the 
Benjamin Franklin Medal for Distinguished Achievement 
in the Sciences (2001), and an Honorary Knighthood of the 
British Empire (2002).
Of particular relevance to the question presented 
to the Court is Dr. Watson’s role in the Human Genome 
Project and his career-long involvement with recombinant 
DNA research. Dr. Watson was one of the earliest 
proponents of sequencing the human genome. In 1988, 
Dr. Watson was appointed Associate Director for Human 
Genome Research at the National Institutes of Health 
(“NIH”) and, in 1989, Director of the National Center for 
Human Genome Research at the NIH. In these positions, 
Dr. Watson initiated and led the public effort to sequence 
the human genome. Even at that time, the question of 
whether human genes should be patented was one of 
critical importance. 
3Given the importance of the question presented, Dr. 
Watson presents his arguments from his personal, unique 
perspective on the issue of whether human genes are 
patentable. 
*  *  *
SUMMARY OF THE ARGUMENT
Human genes should not be patented. First, a human 
gene is fundamentally unique—unlike any ordinary 
“composition of matter.” A gene conveys information—the 
instructions for life. As a product of nature, a human gene’s 
primary purpose is to encode the information for creating 
proteins, enzymes, cells, and all the other components 
that make us who we are. I explained much of this when 
I submitted my amicus brief to the appeals court, but that 
court was unpersuaded. So I reiterate what I told the 
appeals court: Life’s instructions ought not be controlled 
by legal monopolies created at the whim of Congress or 
the courts.
Second, much of what we now know about human 
genes traces back to the Human Genome Project, which 
was structured as a public works project, intended to 
bene t everyone by deciphering our genetic code. Our 
goal was to construct a map of what already existed in 
nature, namely our genes. Accordingly, I, along with other 
prominent scientists, expressed the strong opinion that 
human genes should not be patented. There was simply 
no need for it. Others, including some at the National 
Institutes of Health, disagreed. Eventually, much but 
not all of the human genome was dedicated to the public 
through the efforts of the Human Genome Project. It was 
4a mistake by the Patent Of ce to issue patents on human 
genes and a mistake by those who  led for those patents.
Third, human gene patents are not necessary to 
encourage scientists to advance our knowledge and 
develop innovative new medicines or biotechnology 
inventions. The important innovations needing patent 
protection are not the human genes themselves but 
the technologies that use human genes. And here, it 
is important that the human genes can be reasonably 
accessible so that as many top minds as possible can 
develop the new technologies based on the human genes. 
As you read this, scientists are creating new procedures 
using hundreds, if not thousands, of genes for diagnosing 
and treating life-threatening diseases, including breast 
cancer. Innovation will be rewarded based on those 
developments, not the patenting of the human gene. Thus, 
if it were decided that human genes can be patented, 
courts should grant compulsory licenses. Such licenses 
would ensure access to human genomic information on 
reasonable terms, guaranteeing that our genomic map 
creates the most bene t for mankind.
ARGUMENT
I. Because Human Genes Are Unique And Convey 
Information About The Essence of Being Human, 
They Should Not Be Patented
I have read through the various opinions issued in 
this case.2  The opinions admirably describe the scienti c 
2. I have also read the Supreme Court’s decision in Mayo v. 
Prometheus, although its opaqueness must leave many attorneys 
wondering if it adds anything at all to the issue of whether human 
genes ought to be patented. 
5details of DNA and human genes, but the opinions by the 
appeals court miss the fundamentally unique nature of 
the human gene. Simply put, no other molecule can store 
the information necessary to create and propagate human 
life the way human DNA does. It is a chemical entity, but 
DNA’s importance  ows from its ability to encode and 
transmit the instructions for creating a human being. 
The question presented to this Court is one which, I 
believe, requires an appreciation of the history of human 
DNA research. The appeals court appeared not to fully 
appreciate this history and how it necessarily informs the 
inquiry. Moreover, Congress has not enacted any speci c 
law which says that human genes are patentable. Indeed, 
the nature of the gene—and the double-helical structure 
of DNA on which genes are encoded—mandate that a 
human gene does not fall within the ordinary meaning of 
“composition,” as Congress set forth in the 1952 Patent 
Act.
Even before DNA’s structure was revealed, 
many scientists recognized the importance of a cell’s 
chromosomes (which are composed of DNA) to the 
propagation of life. In 1944, Erwin Schrödinger, a Nobel 
Prize-winning physicist, wrote a small book titled What 
Is Life? In it, he reasoned that chromosomes were the 
genetic information bearers. Schrödinger thought that, 
because so much information must be packed into every 
cell, the information must be compressed into “hereditary 
code-script” embedded in the molecular fabric of the 
chromosomes. The same year, Oswald Avery, Maclyn 
McCarty, and Colin MacLeod provided empirical proof 
that DNA was the genetic material. Even so, many 
skeptical scientists questioned this  nding, until 1952, 
when Alfred Hershey and Martha Chase laid to rest any 
6doubts with their experiments done at Cold Spring Harbor 
Laboratory.
The secret to DNA’s ability to create life is its double 
helical structure, along with its information-coding 
sequences. Francis Crick and I published the  rst correct 
structure of DNA in 1953. J.D. Watson & F.H.C. Crick, 
A Structure for Deoxyribose Nucleic Acid, 171 Nature 
737 (1953). Building on the X-ray crystallographic work 
of Maurice Wilkins and Rosalind Franklin, Francis and 
I determined that DNA forms a double helix. At the time, 
we were in a tight race with Linus Pauling (soon to be 
a Nobel laureate in chemistry and later a laureate for 
the Peace Prize). Fortunately for us, Pauling concluded 
that DNA was a triple helix—an erroneous conclusion 
ironically based on a chemical error made by a most-
brilliant chemist.
 The double-helical structure of DNA epitomizes 
elegance in simplicity. From a chemical perspective, 
DNA is a simple compound, little more than two strands 
of a nucleotide polymer wound together in a double-helix 
formation. The nucleotide polymer consists of various 
sequences of A, T, G, and C bases. The two strands of the 
double helix are complementary to each other.3 
When Francis and I deciphered the structure, we 
immediately understood its significance. With a hint 
of more to come, we wrote in our article that “[i]t has 
3. Amusingly, after I gave my  rst presentation of our DNA 
structure in June 1953, Leó Szilárd, the Hungarian physicist and 
an inventor of the nuclear chain reaction, asked whether I would 
patent the structure. That, of course, was out of the question.
7not escaped our notice that the speci c pairing we have 
postulated immediately suggests a possible copying 
mechanism for the genetic material.” Id. The double-
helix structure confirmed DNA’s role as the genetic 
carrier and created the possibility of almost limitless 
information storage. The various sequences of bases could 
be translated by a cell’s machinery, and that information 
would be used to create new proteins for the cell. 
Following physicist George Gamow’s suggestion, Sydney 
Brenner and Francis Crick later demonstrated that the 
smallest informational unit, the codon, was three bases 
long, e.g., AAA, TTT, etc. 
Later scientists discovered that certain DNA 
sequences controlled the expression of other genes. One 
of the earliest of these control sequences discovered was 
the “TATA box.” The TATA box contains the core DNA 
sequence 5’-TATAAA-3’ or a similar variant. Speci c 
proteins can bind to this sequence, which promotes the 
transcription of other speci c genes. Extracted from 
the chromosome, a nucleic acid molecule having the 
TATAAA sequence has little, physically inherent value. 
Its signi cance arises because that sequence is useful 
information to the cell’s genetic machinery. The TATAAA 
sequence leads to the expression of genes that affect the 
cell and ultimately our human experience. 
The terminology of molecular genetics underscores 
DNA’s informational role in life. In a living cell, DNA 
is used to make RNA, and then RNA is used to make 
polypeptides, i.e., protein. The first step—DNA to 
RNA—is called “transcription.” The second step—RNA 
to proteins—is called “translation.” Both words connote 
the conveyance of information instead of simply the 
8creation of new chemical entities, and for good reason. The 
information encoded by a human gene is  rst transcribed 
into RNA (DNA and RNA are similar molecules, thus 
similar languages, so the genetic information is merely 
transcribed from one format to another). Then, the genetic 
information is translated from RNA into protein. (RNA 
and protein are different biochemical “languages,” hence 
translation). The entirety of the DNA machinery relates 
to transferring and utilizing the genetic information. 
When cells replicate, they make copies of the genetic 
code for the progeny cells. New strands of DNA are 
synthesized in a process analogous to the way scriveners 
of years past would copy legal documents. Just as 
scriveners would copy legal documents word by word, 
a cell copies the DNA molecule letter by letter (A, T, G, 
or C). And just as scriveners proofread their work, the 
DNA polymerase—the enzyme that replicates DNA—
has a built-in proofreading mechanism. But as with all 
proofreading, the system is not perfect, and errors occur. 
“Typographical” errors with DNA replication can lead to 
genetic mutations—which can cause devastating diseases 
or can lead to evolutionary improvements. 
To this day, we continue to learn how human genes 
function. We estimate that humans have approximately 
21,000 genes. We have yet to fully understand the functions 
of all human genes, but this lack of understanding is 
further reason that scientists should be permitted to 
experiment on human genes free from any threat of patent 
infringement. 
The social history of human genes also reveals the 
unique informational component of human DNA that sets 
9it apart from other chemical compounds. In the early part 
of the twentieth century, many in society believed that 
the answers to all of society’s ills resided in the human 
genome. From that belief grew the ill-fated eugenics 
movement, founded on an incomplete understanding of 
human genetics.
Even the esteemed Justice Oliver Wendell Holmes, 
along with some of his colleagues, misunderstood the role 
of genes in human development. In the landmark case 
of Buck v. Bell, 274 U.S. 200, 207 (1927), Justice Holmes 
expressed a view about genetics that prevailed during 
his time:
It is better for all the world, if instead of waiting 
to execute degenerate offspring for crime, or 
to let them starve for their imbecility, society 
can prevent those who are manifestly un t from 
continuing their kind. . . . Three generations of 
imbeciles are enough.
We now know that many factors affect a person’s 
mental acuity, genes being some of them. But Justice 
Holmes and other supporters of the eugenics movement 
could not appreciate, at that time, the precise role of how 
genetics determines and in uences a person. 
In years to come, with the right advances in genetic 
engineering, we may well be able to treat or rectify mental 
disabilities and physical diseases which today are deemed 
incurable. Such hope is all the more reason that scienti c 
research on human genes should not be impeded by the 
existence of unnecessary patents. More importantly, we 
would not want one individual or company to monopolize 
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the legal right to the bene cial information of a human 
gene—information that should be used for the betterment 
of the human race as a whole.
By the 1970s, the public’s perception of DNA and 
genetic technology had reached its nadir. Far from being 
viewed as the vindicator of the wrongfully accused—as the 
public often sees it today—recombinant DNA technology 
was considered by many to be inherently dangerous. In 
fact, various interest groups wanted to ban recombinant 
DNA research.4 Ironically, this hysteria seemed to begin 
after I participated in the first scientific discussions 
exploring whether proposed regulations on DNA research 
were necessary (at the Gordon Research Conference of 
Nucleic Acids in June 1973). 
Unfortunately, the initial ruminations mutated 
into full- edged proposed restrictions, issued from the 
Asilomar Conference in February 1974. Later, in the 
summer of 1976, as the hysteria increased, the National 
Institutes of Health (“NIH”) published guidelines 
governing recombinant DNA research. Shortly after, 
the public discourse reached such a fevered pitch that, 
in the summer of 1976, the Cambridge City Council 
declared a three-month moratorium on all recombinant 
DNA research in the city of Cambridge—and therefore 
at Harvard University and the Massachusetts Institute of 
Technology. These decisions had signi cant consequences, 
in some cases forcing scientists to abandon and discard 
the results of their experimental research.
4. I recount much of this history in one of my books. See James 
D. Watson & John Tooze, The DNA Story: A Documentary History 
of Gene Cloning (1981). Another good article is Michael Rogers, 
The Pandora’s Box Congress, Rolling Stone, June 19, 1975, at 36, 
which is reprinted in The DNA Story.
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Congress also joined the bandwagon of trying to 
regulate recombinant DNA research. In the fall of 1976, 
the late Senator Edward Kennedy, as chair of the Senate 
Health Subcommittee, conducted hearings on whether 
Congress should enact legislation restricting recombinant 
DNA research. Some in Congress even wanted to ban the 
research.
I, of course, did not favor these restrictions. I 
explained at the time that “our Congressmen are being 
asked to decide between two silly alternatives.” J.D. 
Watson, In Defense of DNA, The New Republic, June 25, 
1977, at 11. At one point, I had to defend recombinant DNA 
research from the attacks of the actor Robert Redford, 
who, along with the Environmental Defense Fund, raised 
money hoping to halt basic research experiments using 
recombinant DNA. See James D. Watson, The Nobelist vs. 
The Film Star: DNA Restrictions Attacked, Washington 
Post, May 14, 1978, at D1. Other prominent scientists, 
including but not limited to Joshua Lederberg and Stanley 
Cohen, were vocal in their defense of recombinant DNA 
research. Eventually, reason and objectivity prevailed, 
NIH loosened its guidelines, and Congress refrained from 
enacting detrimental legislation. Scientists were again 
free to conduct their recombinant DNA research without 
absurd restrictions.
My point with this overly brief and incomplete history 
of the early days of recombinant DNA research is to 
illustrate how those major controversies associated with 
human genes arose because human genes are much more 
than chemical compounds. The myopic perspective thinks 
of a human gene as merely another chemical compound—
another composition—consisting of various bases and 
12
sugars wrapped together in a double helix. Science and 
history teach us otherwise, however. 
During the height of the hysteria, a popular columnist 
for the San Francisco Chronicle asked, “Why will 
scientists persist in playing God?” See James D. Watson 
& John Tooze, The DNA Story: A Documentary History 
of Gene Cloning 165 (1981) (reprinting Charles McCabe, 
On Playing God, San Francisco Chronicle, Apr. 4, 1977). 
We were not playing God, but that is what many people 
thought—not because of who we were but because we were 
working with the instructions for creating human life.
Human genes—quintessential products of nature—
are useful because they convey vital information. The 
human genome’s ability to be our instruction book on 
life distinguishes human DNA from all other chemicals 
covered by the patent laws. No other molecule carries 
the information to instruct a human zygote to become a 
boy or a girl, a blonde or brunette, an Asian, African, or 
Caucasian.
Some may suggest that all the above has little 
relevance to whether human genes are patentable. But 
that suggestion ignores the important social consequences 
of restricting the use of human genes. Our history 
con rms that a human gene is not just another chemical 
compound. A human gene is a product of nature and is 
more than simply a fragment of a longer DNA polymer. 
A human gene’s patentability cannot depend simply on 
whether a covalent bond is broken during puri cation. 
Human genes—unlike any other chemical composition—
reveal information that can be important in life-or-death 
situations. The information contained in our genes lets 
13
us predict our future. With a gene sequence in hand, we 
can know with some degree of certainty whether we will 
develop cancer, a neurological disease, or some other 
malady. This information should not be monopolized by 
any one individual, company, or government. 
II. The Human Genome Project Was Intended To 
Bene t All, Not Just Select Companies
In addition to understanding the uniqueness of human 
DNA, an awareness of the Human Genome Project’s 
history should guide the Court to the correct decision 
that human genes, as products of nature, should not be 
patented. The Human Genome Project was started not 
to increase the pro ts of select companies but to expand 
our understanding of the human genome and make this 
information available to all scientists. To permit patent 
monopolies on human genes would contravene the spirit 
of the multinational, taxpayer-subsidized, public works 
effort to sequence the human genome. 
The genesis of the Human Genome Project dates 
to the mid-1980s, when the dual technological advances 
of recombinant DNA and computers opened the door to 
deciphering the human genome. In June 1986, I organized 
a special session at Cold Spring Harbor Laboratory to 
discuss the beginnings of what would become the Human 
Genome Project. At that time, the U.S. Department of 
Energy had also begun to focus on sequencing the genome. 
Other eminent scientists joined the early effort, including 
but certainly not limited to Bruce Alberts, Sydney 
Brenner, and David Botstein. Eventually, we published 
our report (from the National Academy of Sciences) 
making the case for sequencing the human genome. With 
14
the support of James Wyngaarden, then-head of NIH, 
and many others, the Human Genome Project became a 
reality.
In May 1988, I was appointed Associate Director for 
Human Genome Research of NIH (and later, in 1989, 
became NIH’s Director of the National Center for Human 
Genome Research). In these positions, my role was to 
oversee a multimillion-dollar budget and to organize 
what had become a multi-agency, international effort to 
decipher the human genome. The United States directed 
the project and carried out half of the work, while the 
rest was done mainly in the United Kingdom, France, 
Germany, and Japan. 
Even at the early stages of the project, we were 
concerned about the issue of patenting human genes. Most, 
although not all, eminent scientists recognized that human 
genes should not be monopolized by patents. I believed 
at the time—and continue to believe—that the issue of 
patenting human genes went to the very crux of whether 
the information encoded by human DNA should be freely 
available to the scienti c community and the public at 
large. Some twenty years ago, I explained that patenting 
human genes was lunacy, and I was not a lone voice. 
Sadly, and to the detriment of scienti c research, my 
view did not control the policy decisions of NIH, which 
had  led for numerous patents covering human genes. 
Even more egregious were the types of patents being  led 
on human genes. Many of NIH’s patents described only 
small fragments of genes and other unknown sequences 
of the human genome. In June 1991, an NIH of cial had 
urged Craig Venter, who at the time was working at NIH, 
15
to  le patent applications on several hundred new DNA 
sequences, even though, in many instances, neither Venter 
nor NIH had any inkling of what those sequences did. The 
following year, Venter listed over 2,000 more sequences 
in his patent applications, still having no clue about the 
function of those sequences. It was preposterous to grant 
patents on genes, fragments of genes, random bits of 
human DNA, and who knows what else when the scientists 
themselves had no clue as to what the DNA sequences did. 
I expressed my objections to NIH management, 
but to no avail. To me, it was clear that the purpose of 
the Human Genome Project was to map and publish the 
human genome sequence for the scienti c community. 
It was not to provide raw data to individual companies 
seeking government-backed exclusivity on the genetic 
code. As the then-leader of the project, I felt a particular 
obligation to do what I could. In my view, 
[t]he Human Genome Project is much more 
than a vast roll call of As, Ts, Gs, and Cs: it is as 
precious a body of knowledge as humankind will 
ever acquire, with a potential to speak to our 
most basic philosophical questions about human 
nature, for purposes of good and mischief alike.
James D. Watson, DNA: The Secret of Life 172 (2003). In 
1992, I publicly opposed NIH’s decision to patent human 
genes. As a result, I was left with no choice and therefore 
resigned from NIH that year. 
By that time, the Project was well underway, and I felt 
comfortable that my departure would not have a negative 
effect. Notably, patenting human genes was not necessary 
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to complete the Human Genome Project. Indeed, the 
international effort was proceeding on schedule without 
any need to  le patent applications on human genes. 
Fortunately, my successor, Francis Collins, had the 
good sense to understand that gene patenting was not 
necessary and inhibited fundamental research. He later 
explained that “[t]he information contained in our shared 
instruction book is so fundamental, and requires so much 
further research to understand its utility, that patenting 
it at the earliest stage is like putting up a whole lot of 
unnecessary toll booths on the road to discovery.” Francis 
Collins, The Language of Life: DNA and the Revolution 
in Personalized Medicine (2010). 
Less than  fteen years after its start, the Human 
Genome Project, along with Celera Genomics, achieved 
success. On June 26, 2000, President Bill Clinton and 
Prime Minister Tony Blair announced that the two groups 
had  nished a working draft, which was published for the 
public in February 2001. Gaps in the rough draft were 
 lled in by 2003— fty years after Crick and I published 
the structure of DNA. Scientists have used the data to 
estimate that humans have approximately 21,000 genes—
in some sense a surprisingly small number compared to 
other organisms.
The Human Genome Project was a multi-agency, 
international effort. It was funded in large part by 
taxpayer money, and the primary expectation was that 
the information derived from the sequenced human genes 
would be available for all scientists to use. Unfortunately, 
a decade later, private companies are still trying to 
unnecessarily restrict access to human genes and the 
information encoded in those genes. This situation burdens 
17
all of society. Other scientists involved in the Human 
Genome Project continue to warn about the harms caused 
by patenting human genes. John Sulston, who received 
the 2002 Nobel Prize in Physiology or Medicine, headed 
the British effort of the Human Genome Project. He has 
explained that “many human genes have patent rights 
on them and this is going to get in the way of treatment 
unless you have a lot of money.” See Alok Jha, Human 
Genome Project Leader Warns Against Attempts to 
Patent Genes, The Guardian, June 24, 2010, at http://
www.guardian.co.uk/science/2010/jun/24/ human-genome-
project-patent-genes.
Fortunately, much of the human genome was placed 
in the public domain. The Human Genome Project made 
efforts to ensure that gene sequences were published as 
soon as possible. The publication of the sequence limited 
the number of patents on human genes. Nonetheless, 
private entities, the NIH, and other entities have obtained 
patents on some of these genes. Eventually, the problem 
will disappear, as those patents expire. But in the interim, 
the Court should rule that human genes, as products of 
nature, are not patentable.
III. Human Gene Patents Are Not Necessary, But If 
They Are Granted, Compulsory Licenses Should 
Be Granted To Ensure Fair Access
In general, lawyers and judges misunderstand 
scientific research when they contend that patent 
protection is necessary to encourage scientists to discover 
human genes. A scientist does not—and should not—
expect to obtain a legal monopoly over the information 
encoded by human genes. And the average scientist should 
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not expect a windfall simply for revealing the sequence of 
DNA bases that encode various genes. Research on human 
genes is one of those rare endeavors which should be—and 
is—done with the understanding that, although inventions 
based on those genes may later be commercialized, the 
genes themselves are to be employed for the maximum 
bene t of humankind. 
Consider  a lso  whether  a  biot echnolog y or 
pharmaceutical company derives major revenue from the 
sales of human genes. From what I have seen, the answer 
is generally no. Most biotechnology and pharmaceutical 
companies do not derive much, if any, revenue from selling 
or licensing human genes. Rather, their primary revenue 
comes from products and services, such as pharmaceutical 
drugs or research tools, that might be based on human 
genes. The Court should not be overly concerned that 
banning patents on human genes will cause a detrimental 
loss of revenue.
Patenting human genes also deters and obstructs 
advances in genetic technologies that require the use and 
evaluation of multiple genes. For instance, investigators at 
the University of Washington have developed parallel gene 
sequencing methods for identifying inherited mutations 
in breast and ovarian cancer genes. See Tom Walsh, et al., 
Detection of Inherited Mutations for Breast and Ovarian 
Cancer Using Genomic Capture and Massively Parallel 
Sequencing, 107 Proceedings of the National Academy of 
Science USA 12,629 (2010). This group’s approach uses 
multiple genes, not just the speci c BRCA1 and BRCA2 
genes in the Myriad patents, to estimate cancer risk. 
My own recent investigations have highlighted 
the complicated genetic basis of human diseases. For 
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instance, complete genome sequencing is advancing 
our understanding of complex neurological diseases, 
such as schizophrenia, autism, Alzheimer’s disease, and 
Parkinson’s disease, to name just a few. See Huda Akil, 
et al., The Future of Psychiatric Research: Genomes and 
Neural Circuits, 372 Science 1580 (2010). It is becoming 
increasingly clear that the etiology of many neurological 
diseases will encompass multiple human genes, acting in 
concert. 
Cancer research is also becoming increasingly 
dependent on a better understanding of the genetic 
mechanisms underlying the root causes of cancer. See 
Jim Watson, Oxidants, Antioxidants and the Current 
Incurability of Metastatic Cancers, 2013 Open Biology 
120144 (Jan. 9, 2013). Speci cally, it is imperative that 
“RNAi methodologies” be employed to identify the 
remaining major molecular targets for future anticancer 
drug development. 
A human genome cluttered with no trespassing signs 
granted by the Patent Of ce inhibits scienti c progress, 
particularly the development of useful tests and medicines 
in areas requiring multiple human genes. The resources 
devoted to cancer research, neurological diseases, and 
other areas will be diverted to concerns about whether one 
can use a particular human gene. For a new assay using 
hundreds of human genes, the sea of patents and patent 
applications would create hundreds, if not thousands, of 
individual obstacles to developing and commercializing the 
assay. The best way, in my view, to resolve this problem is 
to eliminate the unnecessary patenting of human genes.
If, for some reason, patents on human genes are 
deemed necessary, the next best, albeit imperfect, solution 
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is to require those patent holders to license the patents 
to other researchers so that scienti c progress is not 
obstructed. This is often called a “compulsory license.” In 
my view, a compulsory license can establish reasonable 
access to human genes and genetic information—which 
is what scientists in general want, had the lawyers and 
courts not complicated matters. Reasonable access 
facilitates scienti c and social progress. 
Compulsory licensing would ensure that scientists and 
the public will have reasonable access to human genes and 
genetic information. Compulsory licensing will attenuate 
the negative consequences of the genetic monopolies 
created by patents. Implementing a compulsory license 
protocol will also reduce the risk that a patient is denied 
access to life-saving medicines and technologies using 
human genes and the information encoded in the genes.
Companies and inventors should not fear the 
prospect of compulsory l icensing of human gene 
patents. The inventors and investors would continue to 
receive an appropriate return on their inventions and 
investments. The upside will be that more researchers 
will have meaningful access to the essential tools for 
investigating and understanding the human genome. Best 
of all, compulsory licensing will diminish the frightening 
possibility that patients cannot get a second medical 
opinion. No patient should be subjected to single-source 
diagnostic testing of a potentially life-altering genetic 
condition. When viable alternative, gene-based diagnostics 
exist, a patent should not preclude the availability of those 
alternatives. 
Finally, I do not suggest that all patents relating 
to recombinant DNA technology should be abolished or 
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denied. Scientists have developed many new and useful 
innovations based on recombinant DNA technology. In the 
1970s, Herbert Boyer and Stanley Cohen started Genentech 
based on their pioneering work with recombinant DNA. 
Since then, countless companies have come and gone, 
advancing the state of the art for recombinant DNA and 
adding to the storehouse of knowledge along the way. 
Indeed, this Court itself has recognized that a genetically 
engineered bacterium—a man-made invention using 
recombinant DNA technology—can be a patentable 
invention. Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
Scientists and companies will certainly continue their 
innovative efforts in the areas of personalized medicine, 
genome sequencing, recombinant DNA, and related areas. 
Before too long, it will cost less than $100 to sequence 
an individual’s entire genome. Low-cost sequencing is 
set to revolutionize entire sectors of medical treatment. 
Scientists and inventors will continue to be rewarded for 
their innovations based on human genes. But governments 
have an obligation to ensure that these scienti c advances 
are not thwarted or delayed by ill-informed policies 
restricting the use of the genes themselves. 
Looking past the four words of the question presented, 
the ultimate inquiry is what decision will best promote 
scientific research on human genetics and medicine. 
That, after all, is what the Constitution requires when 
it authorizes patents that promote the progress of the 
“useful arts.” U.S. Const. art. I, § 8, cl. 8. Indeed, as I 
have written before, “[g]ood patents, I would suggest, 
strike a balance: they recognize and reward innovative 
work and protect it from being ripped off, but they also 
make new technology available to do the most good.” 
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James D. Watson, DNA: The Secret of Life 122 (2003). 
And when all is considered, patents on human genes are 
not good patents. 
*  *  *
CONCLUSION
For the foregoing reasons, Dr. Watson respectfully 
submits that the Court should hold that human genes are 
a product of nature and therefore the information encoded 
by those genes cannot be monopolized by any single entity.
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